اختيار الموقع            تسجيل دخول
 

تصفح المحتوي RDA
التصفح حسب الموضوعات
التصفح حسب اللغة
التصفح حسب الناشر
التصفح حسب تاريخ النشر
التصفح حسب مكان النشر
التصفح حسب المؤلفين
تصفح الهيئات
التصفح المؤتمرات
التصفح حسب نوع المادة
التصفح حسب العلاقة بالعمل
تم العثور علي : 1470
 تم العثور علي : 1470
  
 
إعادة البحث

Thesis 2023.

Thesis 2023.

Articles 2022
Volume 39, Issue 1 (March and April 2022) /

Thesis 2023.
The goal of the current thesis was to formulate niosomes of acemetacin (ACM) and
mefenamic acid (MEF) and developed them to improve their tumor targeting in
addition to radio-kinetic evaluation performed using 131I. Niosomes were prepared by
ether injection method and characterized for particle size (PS)
- polydispersity index
(PDI)
- zeta potential (ZP) - entrapment efficiency (EE%) and in vitro drug release.
Factors affecting radiolabeling with 131I were studied and optimized. Radio-kinetic
evaluation was done for 131I-ACM optimum niosomal and 131I-MEF optimum niosomal
formula by intravenous (I.V) administration to solid tumor bearing mice and compared
to I.V 131I-ACM solution and I.V 131I-MEF solution as a control
- respectively. The
average droplet size
- zeta potential and in vitro release after 24 h for the optimum ACM
niosomal formula were 315.23 ± 5.37 nm
- − 9.16 ± 2.91 and 76 % - respectively. The
greatest labeling yield of 131I-ACM was 93.1 ± 1.1%. Radio-kinetic evaluation showed
a maximum tumor uptake of 5.431 %ID/g for 131I-ACM niosomal formula and 2.601
%ID/g for 131I-ACM solution at 60 min post I.V. injection. While the average PS and
ZP values for the optimum MEF niosomal formulation were 247.23 ± 2.32 nm and –
28.3 ± 1.21
- respectively. In vitro release study of the optimum formula showed
appropriate cumulative drug release of (77.73 %) after 24 hr. The highest labeling yield
of 131I-MEF was 98.7  0.8%. The biodistribution study revealed that the highest tumor
uptake of 131I-MEF niosomal formula and 131I-MEF solution at 60 min after I.V.
injection were 2.73 and 1.94 % ID/g
- respectively.
As a conclusion
- ACM-loaded niosomes and MEF-loaded niosomes are excellent
substitutes in cancer treatment due to enhanced tumor uptake of 131I-ACM and 131IMEF
by passive targeting of the nanosized niosomes
- which was confirmed by
radiokinetic evaluation
- Pharmaceutics - Nano

Thesis 2023.

Articles 2008
(vol.33 No.3 Jun. 2008) / 35 p.
   

Thesis 2023.

Articles 2008
(vol.33 No.1. Feb. 2008) / 22 p.
   

Articles 2009
(vol.34 No.4 aug. 2009) / 16 p.
   

Thesis 2023.


من 147
 







Powered by Future Library Software.All rights reserved © CITC - Mansoura University. Sponsored by Mansoura University Privacy Policy